Prognostic significance of the expression levels of the p16, p15, and p14 genes in dogs with high-grade lymphoma

Veterinary Journal

Volumn 199, Issue 2, 2014, Pages 236-244

  Fujiwara Igarashi, Aki ^a   Goto Koshino, Yuko ^a   Sato, Masahiko ^a   Maeda, Shingo ^a   Igarashi, Hirotaka ^a   Takahashi, Masashi ^a   Fujino, Yasuhito ^a   Ohno, Koichi ^a   Tsujimoto, Hajime ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

DNA methylation; Dog; Lymphoma; P16; Tumor suppressor gene

Indexed keywords

MESSENGER RNA; TUMOR SUPPRESSOR PROTEIN;

ANIMAL; DNA METHYLATION; DOG; DOG DISEASE; GENE EXPRESSION; GENETICS; LYMPHOMA; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; VETERINARY;

ANIMALS; BASE SEQUENCE; DNA METHYLATION; DOG DISEASES; DOGS; GENE EXPRESSION; GENES, P16; LYMPHOMA; MOLECULAR SEQUENCE DATA; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS;

EID: 84895903038     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2013.11.004     Document Type: Article

References (48)

1. Amara K., Trimeche M., Ziadi S., Laatiri A., Hachana M., Korbi S. Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas. Annals of Oncology 2008, 19:1774-1786.
2. Baskin C.R., Couto C.G., Wittum T.E. Factors influencing first remission and survival in 145 dogs with lymphoma: A retrospective study. Journal of the American Animal Hospital Association 2000, 36:404-409.
3. Breen M., Modiano J.F. Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans-man and his best friend share more than companionship. Chromosome Research 2008, 16:145-154.
4. Burnett R.C., Vernau W., Modiano J.F., Olver C.S., Moore P.F., Avery A.C. Diagnosis of canine lymphoid neoplasia using clonal rearrangements of antigen receptor genes. Veterinary Pathology 2003, 40:32-41.
5. Chen M., Voeller D., Marquez V.E., Kaye F.J., Steeg P.S., Giaccone G., Zajac-Kaye M. Enhanced growth inhibition by combined DNA methylation/HDAC inhibitors in lung tumor cells with silenced CDKN2A. International Journal of Oncology 2010, 37:963-971.
6. Chun R., Garrett L.D., Vail D.M. Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma. Journal of Veterinary Internal Medicine 2000, 14:120-124.
7. Devitt J.J., Maranon D.G., Ehrhart E.J., Bachand A.M., Lana S.E., LaRue S.M. Correlations between numerical chromosomal aberrations in the tumor and peripheral blood in canine lymphoma. Cytogenetic Genome Research 2009, 124:12-18.
8. Dobson J.M., Samuel S., Milstein H., Rogers K., Wood J.L. Canine neoplasia in the UK: Estimates of incidence rates from a population of insured dogs. Journal of Small Animal Practice 2002, 43:240-246.
9. Dorn C.R., Taylor D.O., Schneider R., Hibbard H.H., Klauber M.R. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. Journal of the National Cancer Institute 1968, 40:307-318.
10. Drexler H.G. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 1998, 12:845-859.
11. Ettinger S.N. Principles of treatment for canine lymphoma. Clinical Techniques in Small Animal Practice 2003, 18:92-97.
12. Flood-Knapik K.E., Durham A.C., Gregor T.P., Sanchez M.D., Durney M.E., Sorenmo K.U. Clinical, histopathological and immunohistochemical characterization of canine indolent lymphoma. Veterinary and Comparative Oncology 2013, 11:272-286.
13. Fournel-Fleury C., Magnol J.P., Bricaire P., Marchal T., Chabanne L., Delverdier A., Bryon P.A., Felman P. Cytohistological and immunological classification of canine malignant lymphomas: Comparison with human non-Hodgkin's lymphomas. Journal of Comparative Pathology 1997, 117:35-59.
14. Fosmire S.P., Thomas R., Jubala C.M., Wojcieszyn J.W., Valli V.E., Getzy D.M., Smith T.L., Gardner L.A., Ritt M.G., Bell J.S., et al. Inactivation of the p16 cyclin-dependent kinase inhibitor in high-grade canine non-Hodgkin's T-cell lymphoma. Veterinary Pathology 2007, 44:467-478.
15. Fujiwara-Igarashi A., Goto-Koshino Y., Mochizuki H., Maeda S., Fujino Y., Ohno K., Tsujimoto H. Simultaneous inactivation of the p16, p15 and p14 genes encoding cyclin-dependent kinase inhibitors in canine T-lymphoid tumor cells. The Journal of Veterinary Medical Science 2013, 75:733-742.
16. Gardiner-Garden M., Frommer M. CpG islands in vertebrate genomes. Journal of Molecular Biology 1987, 196:261-282.
17. Garrett L.D., Thamm D.H., Chun R., Dudley R., Vail D.M. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. Journal of Veterinary Internal Medicine 2002, 16:704-709.
18. Gil J., Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: All for one or one for all. Nature Reviews Molecular Cell Biology 2006, 7:667-677.
19. Greenlee P.G., Filippa D.A., Quimby F.W., Patnaik A.K., Calvano S.E., Matus R.E., Kimmel M., Hurvitz A.I., Lieberman P.H. Lymphomas in dogs. A morphologic, immunologic, and clinical study. Cancer 1990, 66:480-490.
20. Hahn K.A., Richardson R.C., Hahn E.A., Chrisman C.L. Diagnostic and prognostic importance of chromosomal aberrations identified in 61 dogs with lymphosarcoma. Veterinary Pathology 1994, 31:528-540.
21. Hara E., Smith R., Parry D., Tahara H., Stone S., Peters G. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Molecular and Cellular Biology 1996, 16:859-867.
22. Hosoya K., Kisseberth W.C., Lord L.K., Alvarez F.J., Lara-Garcia A., Kosarek C.E., London C.A., Couto C.G. Comparison of COAP and UW-19 protocols for dogs with multicentric lymphoma. Journal of Veterinary Internal Medicine 2007, 21:1355-1363.
23. Animal Neoplasms: A Systemic Review 1981, Williams and Wilkins, Baltimore, MD, USA, pp. 747-812. H.E. Kaiser (Ed.).
24. Kohno T., Yamada Y., Tawara M., Takasaki Y., Kamihira S., Tomonaga M., Matsuyama T. Inactivation of p14ARF as a key event for the progression of adult T cell leukemia/lymphoma. Leukemia Research 2007, 31:1625-1632.
25. Krishnamurthy J., Torrice C., Ramsey M.R., Kovalev G.I., Al-Regaiey K., Su L., Sharpless N.E. Ink4a/Arf expression is a biomarker of aging. Journal of Clinical Investigation 2004, 114:1299-1307.
26. Lal A., Kim H.H., Abdelmohsen K., Kuwano Y., Pullmann R., Srikantan S., Subrahmanyam R., Martindale J.L., Yang X., Ahmed F., et al. P16(INK4a) translation suppressed by miR-24. PLoS ONE 2008, 3:e1864.
27. Lana S.E., Jackson T.L., Burnett R.C., Morley P.S., Avery A.C. Utility of polymerase chain reaction for analysis of antigen receptor rearrangement in staging and predicting prognosis in dogs with lymphoma. Journal of Veterinary Internal Medicine 2006, 20:329-334.
28. Lossos I.S., Jones C.D., Warnke R., Natkunam Y., Kaizer H., Zehnder J.L., Tibshirani R., Levy R. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 2001, 98:945-951.
29. MacDonald V.S., Thamm D.H., Kurzman I.D., Turek M.M., Vail D.M. Does l-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma?. Journal of Veterinary Internal Medicine 2005, 19:732-736.
30. Masumoto N., Fujii T., Ishikawa M., Saito M., Iwata T., Fukuchi T., Susumu N., Mukai M., Kubushiro K., Tsukazaki K., et al. P16 overexpression and human papillomavirus infection in small cell carcinoma of the uterine cervix. Human Pathology 2003, 34:778-783.
31. Mellanby R.J., Herrtage M.E., Dobson J.M. Owners' assessments of their dog's quality of life during palliative chemotherapy for lymphoma. Journal of Small Animal Practice 2003, 44:100-103.
32. Miller A.G., Morley P.S., Rao S., Avery A.C., Lana S.E., Olver C.S. Anemia is associated with decreased survival time in dogs with lymphoma. Journal of Veterinary Internal Medicine 2009, 23:116-122.
33. Modiano J.F., Breen M., Valli V.E., Wojcieszyn J.W., Cutter G.R. Predictive value of p16 or Rb inactivation in a model of naturally occurring canine non-Hodgkin's lymphoma. Leukemia 2007, 21:184-187.
34. Momoi Y., Okai Y., Watari T., Goitsuka R., Tsujimoto H., Hasegawa A. Establishment and characterization of a canine T-lymphoblastoid cell line derived from malignant lymphoma. Veterinary Immunology and Immunopathology 1997, 59:11-20.
35. Parry D., Bates S., Mann D.J., Peters G. Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. EMBO Journal 1995, 14:503-511.
36. Popov N., Gil J. Epigenetic regulation of the INK4b-ARF-INK4a locus: In sickness and in health. Epigenetics 2010, 5:685-690.
37. Sato M., Kanemoto H., Kagawa Y., Kobayashi T., Goto-Koshino Y., Mochizuki H., Takahashi M., Fujino Y., Ohno K., Tsujimoto H. Evaluation of the prognostic significance of BCL6 gene expression in canine high-grade B-cell lymphoma. The Veterinary Journal 2012, 191:108-114.
38. Setoguchi A., Sakai T., Okuda M., Minehata K., Yazawa M., Ishizaka T., Watari T., Nishimura R., Sasaki N., Hasegawa A., et al. Aberrations of the p53 tumor suppressor gene in various tumors in dogs. American Journal of Veterinary Research 2001, 62:433-439.
39. Shiozawa E., Takimoto M., Makino R., Adachi D., Saito B., Yamochi-Onizuka T., Yamochi T., Shimozuma J., Maeda T., Kohno Y., et al. Hypermethylation of CpG islands in p16 as a prognostic factor for diffuse large B-cell lymphoma in a high-risk group. Leukemia Research 2006, 30:859-867.
40. Sokolowska J., Cywinska A., Malicka E. P53 expression in canine lymphoma. Journal of Veterinary Medicine A: Physiology, Pathology, Clinical Medicine 2005, 52:172-175.
41. Takasaki Y., Yamada Y., Sugahara K., Hayashi T., Dateki N., Harasawa H., Kawabata S., Soda H., Ikeda S., Tomonaga M., et al. Interruption of p16 gene expression in adult T-cell leukaemia/lymphoma: Clinical correlation. British Journal of Haematology 2003, 122:253-259.
42. Thomas R., Seiser E.L., Motsinger-Reif A., Borst L., Valli V.E., Kelley K., Suter S.E., Argyle D., Burgess K., Bell J., et al. Refining tumor-associated aneuploidy through 'genomic recoding' of recurrent DNA copy number aberrations in 150 canine non-Hodgkin lymphomas. Leukemia and Lymphoma 2011, 52:1321-1335.
43. Thomas R., Smith K.C., Ostrander E.A., Galibert F., Breen M. Chromosome aberrations in canine multicentric lymphomas detected with comparative genomic hybridisation and a panel of single locus probes. British Journal of Cancer 2003, 89:1530-1537.
44. Vail D.M., Michels G.M., Khanna C., Selting K.A., London C.A. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0) - A Veterinary Cooperative Oncology Group (VCOG) consensus document. Veterinary and Comparative Oncology 2009, 8:28-37.
45. Valli V.E., San Myint M., Barthel A., Bienzle D., Caswell J., Colbatzky F., Durham A., Ehrhart E.J., Johnson Y., Jones C., et al. Classification of canine malignant lymphomas according to the World Health Organization criteria. Veterinary Pathology 2011, 48:198-211.
46. Valli V.E., Vernau W., de Lorimier L.P., Graham P.S., Moore P.F. Canine indolent nodular lymphoma. Veterinary Pathology 2006, 43:241-256.
47. Veldhoen N., Stewart J., Brown R., Milner J. Mutations of the p53 gene in canine lymphoma and evidence for germ line p53 mutations in the dog. Oncogene 1998, 16:249-255.
48. Vezzali E., Parodi A.L., Marcato P.S., Bettini G. Histopathologic classification of 171 cases of canine and feline non-Hodgkin lymphoma according to the WHO. Veterinary and Comparative Oncology 2009, 8:38-49.